Data from AML show that IDH1/2 mutations lead to increased D-2-HG production, which competes with αKG, resulting in αKG depletion and inhibition of ALKBH2 and FTO activity (Figure 2A). The gene discussed is IDH1; the disease is acute myeloid leukemia.